|
.: Leading On-Line Research Tool for Biomedical Intelligence :.
|
|
|
|
Our Deals & Alliances database, which includes many of the Life Science transactions over the last twenty years,
is updated on a daily basis. We rely on annual reports, regulatory filings, press releases, articles, websites and company contacts
to source this information. Deal economics are subject to timing and we combine the most up-to-date information with the ability
to gain a historical perspective by searching the database. We have summarized key categories of deal types
for your convenience and will continue to update them as our database expands.
Key Lists
 Top 2009 Deals and Alliances by Value
| Source |
Partner |
Deal Value
in $millions |
Date |
UCB S.A.
| GlaxoSmithKline plc
| 669.5 | January 23, 2009 |
GlaxoSmithKline plc
| Biovail Corporation
Biovail Laboratories International SRL
| 510.0 | May 06, 2009 |
Wellstat Therapeutics Corporation
| Sanofi-aventis
| 350.0 | October 21, 2009 |
Zydus Cadila Healthcare Limited
| Eli Lilly & Co
| 300.0 | March 30, 2009 |
Procter & Gamble Company
Procter & Gamble Pharmaceuticals, Inc.
| Ajinomoto Co., Inc.
| 210.0 | July 31, 2009 |
Apitope International NV
| Merck Serono S.A.
Merck KGaA
| 206.4 | January 13, 2009 |
| -- | Microbix Biosystems Inc.
Hunan Biopharmaceutical Co., Ltd.
| 200.0 | October 27, 2009 |
Suvanza Inc. (formerly Hamilton PNG)
| CenterSpan Communications Corporation
| 82.0 | June 02, 2009 |
UCB S.A.
| Shire plc
| 69.5 | February 20, 2009 |
Antisoma Research Limited
| Sanofi-aventis
sanofi-aventis U.S. LLC
| 65.0 | May 12, 2009 |
Top M&A 2009 Stats
| Acquirer |
Target |
M&A Date |
M&A Price in $millions |
| Sanofi-Aventis S.A. (SAN) |
Merial Limited |
September 18, 2009 |
4,000 |
| CSL Limited (CSL) |
Talecris Biotherapeutics Holdings Corp. (TLCR) |
June 09, 2009 |
3,100 |
| Watson Pharmaceuticals, Inc. (WPI) |
Robin Hood Holdings Limited (Arrow Group) |
December 02, 2009 |
1,750 |
| Sandoz International GmbH |
EBEWE Pharma Ges.m.b.H Nfg.KG - Specialty Generic Injectables Business |
September 24, 2009 |
1,257 |
| Astellas Pharma, Inc. (4503) |
CV Therapeutics, Inc. (CVTX) |
April 17, 2009 |
1,000 |
| Sanofi-Aventis S.A. (SAN) |
Medley Pharmaceutical Industry SA |
April 27, 2009 |
680 |
| Stryker Corporation (SYK) |
Ascent Healthcare Solutions, Inc. |
December 31, 2009 |
525 |
| KP Chemical Corp. (064420) |
Pakistan PTA Limited (PPTA) |
September 18, 2009 |
500 |
| Thermo Fisher Scientific, Inc. (TMO) |
B R A H M S Aktiengesellschaft |
October 01, 2009 |
470 |
| Abbott Laboratories (ABT) |
Visiogen, Inc. |
October 20, 2009 |
400 |
|
|
|
| |
 |
The information contained herein is based on sources believed to be reliable but is
neither all-inclusive nor guaranteed by Life Science Analytics ("LSA"). Opinions, if any,
reflect the judgment of LSA at this time and are subject to change. LSA does not undertake
to advise you of changes in their opinion or information. Most of the companies LSA follows
are emerging growth companies whose securities typically involve a higher degree of risk and
more volatility than the securities of more established companies. The securities discussed
in the reports included in LSA's Database may be unsuitable for investors depending on their
specific investment objectives, financial situation and needs. No report included in the LSA
Database is a recommendation that any particular investor should purchase or sell any
particular security in any amount or at all, and is not a solicitation of any offer to
purchase or sell from or to any particular investor. For additional information that may be
available on the securities mentioned, please contact Life Science Analytics.
|
|
|
 |
 |
|
